However, it also showed that individuals having high CD4 counts (>500 cells/μl), high CD4 nadir (>200 cells/μl) and undetectable virus levels (<50 copies/ml) can safely undergo treatment interruptions in carefully monitored clinical trials without increasing their risk of death and non-AIDS events or developing viral resistance [115,124–126]. This evidence concerns the gene CD4 and AIDS.